MONTREAL — An investigational targeted immunotherapy for Guillain-Barré syndrome (GBS) more than doubled improvement in disability after 8 weeks compared with placebo and showed sustained benefit at ...

Dear Dr. Roach: You have written about immunocompromised people before, but what about those of us who have immune systems that overreact instead of underperform, such as with Guillain-Barre syndrome?

Five-year-olds can be goofy. That was my first thought several years ago when my son stumbled and fell to the ground. But when he failed to get up and told us that his legs hurt, my husband and I grew ...